Design, synthesis, and biological evaluation of 5-chlorine-2-amino-pyrimidine derivatives as potent PLK4 inhibitors

Shuyi Mu, Wenqiang Sun, Zehui Qi, Minghui Tong, Xuan Shi, Han Wang, Nian Liu, Pengkun Sun, Cunzheng Fan, Ningyuan Hu, Yixiang Sun, Haoyu Zhang, Zixuan Gao, Dongmei Zhao and Maosheng Cheng

RSC Med. Chem., 2025, 16, 4997
DOI: 10.1039/D5MD00435G

Design, synthesis, and biological evaluation of novel N-(1H-indazol-6-yl)benzenesulfonamide derivatives as potent PLK4 inhibitors

Pengkun Sun, Cunzheng Fan, Nian Liu, Minghui Tong, Xuan Shi, Han Wang, Shuyi Mu, Ningyuan Hu, Yixiang Sun, Haoyu Zhang, Zixuan Gao, Dongmei Zhao and Maosheng Cheng

RSC Med. Chem., 2025, 16, 3551
DOI: 10.1039/D5MD00251F

Polo-like kinase 4 (PLK4) as a therapeutic target in breast cancer

Armen Parsyan, Harjot Athwal, Vasudeva Bhat and Alison L Allan

Carcinogenesis, 2025, 46
DOI: 10.1093/carcin/bgaf067

Therapeutic potential of targeting polo-like kinase 4

Qian Lei, Quanwei Yu, Na Yang, Zhaolin Xiao, Chao Song, Rui Zhang, Shuxin Yang, Zhihao Liu and Hui Deng

European Journal of Medicinal Chemistry, 2024, 265, 116115
DOI: 10.1016/j.ejmech.2023.116115

Rational design of CZL-S092: A novel indazole-based PLK4 inhibitor targeting neuroblastoma through virtual screening and fragment-based drug design strategies

Nian liu, Ningyuan Hu, Cunzheng Fan, Minghui Tong, Xuan Shi, Han Wang, Pengkun Sun, Shuyi Mu, Zehui Qi, Wenqiang Sun, Haoyu Zhang, Yixiang Sun, Zixuan Gao, Dongmei Zhao and Maosheng Cheng

European Journal of Medicinal Chemistry, 2025, 296, 117867
DOI: 10.1016/j.ejmech.2025.117867